哌柏西利治疗乳腺癌的临床研究进展  

Clinical research progress of palbociclib in treatment of breast cancer

作　　者：王智 周鑫[1,2] 何雪茹 付裕豪 荀雪姣 李颖 董占军[2] WANG Zhi;ZHOU Xin;HE Xueru;FU Yuhao;XUN Xuejiao;LI Ying;DONG Zhanjun(Graduate School of Hebei Medical University,Shijiazhuang 050017,Hebei,China;Hebei General Hospital,Shijiazhuang 050051,Hebei,China)

机构地区：[1]河北医科大学研究生学院,河北石家庄050017 [2]河北省人民医院药学部,河北石家庄050051

出　　处：《中国临床药理学与治疗学》2023年第2期205-213,共9页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：河北省医学科学研究课题(20210037)。

摘　　要：哌柏西利是一种同类首创的细胞周期蛋白依赖性激酶4/6抑制剂,是抗肿瘤药物发展史上一个重要的里程碑。哌柏西利联合芳香化酶抑制剂或氟维司群作为一线、二线或后线治疗,对激素受体阳性、人表皮生长因子受体-2阴性的局部晚期或转移性乳腺癌有良好的疗效和安全性,应用前景较好。本文总结了哌柏西利相关的临床研究和安全性研究等问题。Palbocicril,the first cyclin-dependent kinases 4 and 6 inhibitors,is a crucial milestone in the development history of antineoplastic drugs.It combined with aromatase inhibitor or fulvestrant as first-line,second-line or post-line therapy has good efficacy and safety for hormone receptor-positive,human epidermal growth factor receptor-2 negative locally advanced or metastatic breast cancer,which has a good application prospect.This article summarizes the clinical trials and safety studies related to palbociclib.

关 键 词：哌柏西利 乳腺癌 临床研究 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]